The primary objective of this study is to assess the safety and efficacy of the J-Valve Transfemoral (TF) System in patients with symptomatic, severe (grade 3 or 4), native aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease, who are judged by a multi-disciplinary heart team to be at high risk for open surgical aortic valve replacement (SAVR).

开始日期2024-07-01

申办/合作机构

Minneapolis Heart Institute Foundation, Inc.

[+2]

NCT05531084 / Not yet recruitingN/AIIT

Safety and Effectiveness of Surgeon-Modified Fenestrated and Branched Endografts in Treating Subjects With Complex Aortic Aneurysms

The primary objective of the present study is to evaluate the safety, effectiveness, and clinical outcomes of surgeon-modified fenestrated stent grafts used to treat patients with failed previous infrarenal repairs (failed EVAR) and complex aortic aneurysms (thoracoabdominal, juxtarenal, pararenal, and paravisceral aneurysms).

开始日期2022-10-01

申办/合作机构

Minneapolis Heart Institute Foundation, Inc.

[+1]

NCT05440084 / Not yet recruitingN/AIIT

Impact of Chronic Total Occlusion Percutaneous Coronary Intervention on Regular Physical Activity

Heart disease is a leading cause of death in the US. . Heart blood vessel chronic total occlusions are 100% blockages of the heart vessels. These patients often suffer from chest pain, shortness of breath, and depression. Heart doctors thread special cables from the groin and wrist to the heart and open up these 100% blocked vessels. . This treatment improves symptoms and quality of life. Exercise is very beneficial for health. Previous studies suggest that even a 1000 steps/day increase in daily steps can improve health. But, patients with occluded heart vessels are often inactive because they have chest pain, feeling tired, or are short of breath. It is unknown whether opening these 100% blocked heart vessels will help patients have a more active lifestyle, which is good for health. The goal is to measure the impact of opening these occluded heart vessels on daily exercise in this project. Specifically, the investigators will give a smart watch to patients referred for this treatment. The smart watch will track the patients' daily steps before and after the procedure.

开始日期2022-09-01

申办/合作机构

Minneapolis Heart Institute Foundation, Inc.

100 项与 Minneapolis Heart Institute Foundation, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Minneapolis Heart Institute Foundation, Inc. 相关的专利（医药）

登录后查看更多信息

843

项与 Minneapolis Heart Institute Foundation, Inc. 相关的文献（医药）

2024-12-01·International Journal of Cardiology

The therapeutical role of balloon aortic valvuloplasty: Back to the origin?

Letter

作者: Margonato, Davide

2024-10-01·JACC: Advances

Repolarization Injury and Occurrence of Torsades de Pointes During Acute Takotsubo Syndrome

Article

作者: Sharkey, Scott W ; Brilakis, Emmanouil S. ; Hauser, Robert G. ; Vemmou, Evangelia ; Basala, Thomas ; Brilakis, Emmanouil S ; Sharkey, Scott W. ; Nikolakopoulos, Ilias ; Hauser, Robert G ; Xenogiannis, Iosif ; Bergstedt, Seth ; Witt, Dawn

BackgroundDuring takotsubo syndrome (TS), QTc prolongation is common, reflecting repolarization injury and providing the substrate for torsades de pointes (TdP). TdP has been reported sporadically in TS, yet QTc prolongation and TdP risk are often overlooked during management.ObjectivesIn TS patients, we sought to document TdP incidence, characteristics of patients with TdP, and association of QTc with postdischarge survival.MethodsAmong consecutive TS patients at a single institution, we documented admission and discharge QTc, TdP incidence, and postdischarge 1-year mortality from 2006 to 2019. For perspective regarding TdP-TS risk, we characterized all published TdP cases from 2003 to 2022.ResultsOf 259 patients, median age was 68 (range: 59-77) years; 92% were female. The QTc interval was prolonged (≥460 ms) on admission in 129 (49.8%) patients and at discharge in 140 (54%) patients. QTc was ≥500 ms either on admission or at discharge in 98 (37.8%) patients. In-hospital TdP incidence was 0.8%. Postdischarge mortality was associated with admission but not discharge, QTc: <460 ms (1.6%); 460-499 ms (12.6%); ≥500 ms (8.8%); P = 0.0056. Among 38 published TdP-TS cases, 80% of TdP events were within 48 hours of hospitalization, 90% of events occurred with QTc ≥500 ms, and 47.5% of events occurred with QTc ≥600 ms. Conditions associated with TdP risk were present in fewer than one-third of patients.ConclusionsDuring TS, QTc ≥500 ms was frequent. TdP incidence was low, with unpredictable occurrence and observed almost entirely with QTc ≥500 ms. A normal admission QTc was associated with >98% survival at 1-year postdischarge.

2024-09-01·Mayo Clinic Proceedings

High Baseline High-Sensitivity Cardiac Troponin T Concentrations and Risk of Index Acute Myocardial Infarction

Article

作者: Sandoval, Yader ; Mehta, Ramila A ; Lewis, Bradley ; De Michieli, Laura ; Gulati, Rajiv ; Slusser, Josh ; Gharacholou, S Michael ; Jaffe, Allan S ; Ola, Olatunde ; Yang, Eric H ; Knott, Jonathan D ; Akula, Ashok

OBJECTIVETo evaluate the diagnostic performance of the previously recommended baseline high-sensitivity cardiac troponin T (hs-cTnT) thresholds of 52 and 100 ng/L in identifying patients at high risk of acute myocardial infarction (AMI).PATIENTS AND METHODSThis study compared the positive predictive value (PPV) for index AMI of these high-risk hs-cTnT thresholds in adult patients in the emergency department undergoing hs-cTnT measurement.RESULTSThe adjudicated MAyo Southwest Wisconsin 5th Gen Troponin T ImplementatiON cohort included 2053 patients, with 157 (7.6%) who received a diagnosis of AMI. The hs-cTnT concentrations of greater than 52 and greater than 100 ng/L resulted in PPVs of 41% (95% CI, 35%-48%) and 57% (95% CI, 48%-66%). In patients with chest discomfort, hs-cTnT concentrations greater than 52 ng/L resulted in a PPV of 66% (95% CI, 56%-76%) and hs-cTnT concentrations greater than 100 ng/L resulted in a PPV of 77% (95% CI, 65%-87%). The CV Data Mart Biomarker cohort included 143,709 patients, and 3003 (2.1%) received a diagnosis of AMI. Baseline hs-cTnT concentrations greater than 52 and greater than 100 ng/L resulted in PPVs of 12% (95% CI, 11%-12%) and 17% (95% CI, 17%-19%), respectively. In patients with chest pain and hs-cTnT concentrations greater than 52 ng/L, the PPV for MI was 17% (95% CI, 15%-18%) and in those with concentrations greater than 100 ng/L, only 22% (95% CI, 19%-25%).CONCLUSIONIn unselected patients undergoing hs-cTnT measurement, the hs-cTnT thresholds of greater than 52 and greater than 100 ng/L provide suboptimal performance for identifying high-risk patients. In patients with chest discomfort, an hs-cTnT concentration of greater than 100 ng/L, but not the European Society of Cardiology-recommended threshold of greater than 52 ng/L, provides an acceptable performance but should be used only with other clinical features.

项与 Minneapolis Heart Institute Foundation, Inc. 相关的新闻（医药）

2022-09-01

·PRNewswire

GlobalVetLink and Heart + Paw Announces Partnership to Streamline Clinic Processes

Heart + Paw has implemented the GlobalVetLink Compliance Assistant platform in their veterinary hospitals to streamline pet travel appointments AMES, Iowa, Sept. 1, 2022 /PRNewswire/ -- Heart + Paw has partnered with GlobalVetLink to implement the GlobalVetLink Compliance Assistant in their veterinary hospitals across the Northeast. The GVL Compliance Assistant is a comprehensive SaaS platform designed to streamline animal health compliance for all veterinary practices. Adding the GlobalVetLink platform to a veterinary hospital's suite of tools allows for seamless compliance and increased efficiency for veterinarians and hospital staff. "Enabling our team with the GVL software was integral in our continued focus to bring innovative solutions into our Heart + Paw practices,"said Dr. George Melillo, Co-Founder and Chief Veterinary Officer at Heart + Paw. "As our pet parents significantly increased the demand for travel we needed to streamline our process with GlobalVetLink. GlobalVetLink is the only solution in the market to truly tackle a demanding and necessary service for the industry." The GlobalVetLink Compliance Assistant platform is used by over 10,000 veterinary practices for creation and electronic submission of compliant health records for companion, production, and equine focused practices. The GVL Pet TravelPass automates regulatory research with built-in intelligent rule checking to streamline International and Hawaii pet travel. This replaces time consuming manual research processes and eliminates mistakes that prevent many veterinary practices from offering pet travel documentation services. "We are thrilled to partner with Heart + Paw to bring our technology to their practices and their teams," said Daniel Levine, Chief Revenue Officer at GlobalVetLink. "Being able to streamline the workflow for the practices allows the team to truly focus on health outcomes. As veterinary practices are faced with challenges from staff shortages, increased demand for pet travel, and continued demand for services, we are looking forward to assisting more practices who need to streamline their health certificate process." GlobalVetLink is the leading digital animal health company. Over 180 million animals per year in the pet travel, equine, and production animal sectors utilize GlobalVetLink's health records for state, federal, and international animal health compliance. Learn more at globalvetlink.com. About GlobalVetLink GlobalVetLink empowers and supports people to provide the best in animal care and safety. The GVL Compliance Assistant is a comprehensive SaaS platform designed to streamline animal health compliance for all veterinary practices. The Certificate Creator is the core of the platform and is managed by an intelligent Compliance Engine that verifies all certificates are compliant with state, federal and international rules and regulations. The GVL Health Record stores data for easy repeat certificate creation and ensures streamlined access to completed certificates. The Compliance Assistant platform automatically submits key animal health certificates to all 50 state animal health offices, and streamlines the submission to USDA-APHIS for international pet travel. Learn more at globalvetlink.com. Media Inquires: Rebecca Haugland, 515-817-5075, [email protected] SOURCE GlobalVetLINK

合作

100 项与 Minneapolis Heart Institute Foundation, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Minneapolis Heart Institute Foundation, Inc. 相关的转化医学

登录后查看更多信息